Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOGES SISAY

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1649264896
CMS profile
347171
Location
EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$634.09

41 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $634.09 41

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $182.46 12
Novartis Pharmaceuticals Corporation $163.59 6
Amgen Inc. $140.44 15
Mallinckrodt Hospital Products Inc. $57.77 2
E.R. Squibb & Sons, L.L.C. $44.07 3
PFIZER INC. $19.50 1
Sobi, Inc $13.70 1
ADMA BioManufacturing LLC $12.56 1

Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOGES SISAY

NPI 1649264896 · CMS profile ID 347171

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOGES SISAY, NPI 1649264896, CMS profile ID 347171. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MOGES SISAY, NPI 1649264896, CMS profile ID 347171. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MOGES SISAY, NPI 1649264896, CMS profile ID 347171, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–41 of 41 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1649264896?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

41 matching records · $634.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 41 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–41 of 41.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $17.8912/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384127 CMS
Novartis Pharmaceuticals Corporation $8.2911/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384125 CMS
ABBVIE INC. $19.3911/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617985 CMS
Amgen Inc. $8.0611/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469805 CMS
Mallinckrodt Hospital Products Inc. $37.2410/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937526277 CMS
ABBVIE INC. $17.7609/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617983 CMS
ABBVIE INC. $9.4309/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617981 CMS
PFIZER INC. $19.5009/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949322871 CMS
Amgen Inc. $11.2709/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469803 CMS
ABBVIE INC. $27.3908/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617979 CMS
Sobi, Inc $13.7008/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940366985 CMS
Amgen Inc. $11.0908/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469801 CMS
Novartis Pharmaceuticals Corporation $40.2208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384111 CMS
Mallinckrodt Hospital Products Inc. $20.5308/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937526275 CMS
Amgen Inc. $10.3808/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469799 CMS
Amgen Inc. $10.7307/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469797 CMS
Amgen Inc. $8.9907/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469795 CMS
ABBVIE INC. $17.5707/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617977 CMS
Amgen Inc. $10.1907/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469793 CMS
Amgen Inc. $10.9806/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469791 CMS
Amgen Inc. $9.2006/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469787 CMS
ABBVIE INC. $14.5706/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617975 CMS
Amgen Inc. $10.2806/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469785 CMS
Amgen Inc. $11.6606/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469789 CMS
ABBVIE INC. $18.0605/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617973 CMS
ABBVIE INC. $22.6005/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617971 CMS
ABBVIE INC. $7.1805/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617969 CMS
ABBVIE INC. $6.4704/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617967 CMS
ADMA BioManufacturing LLC $12.5604/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933558965 CMS
Amgen Inc. $8.4004/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469783 CMS
ABBVIE INC. $4.8303/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617965 CMS
E.R. Squibb & Sons, L.L.C. $12.8203/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932530141 CMS
Amgen Inc. $5.1003/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469781 CMS
Novartis Pharmaceuticals Corporation $62.0203/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384107 CMS
Amgen Inc. $5.8602/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469779 CMS
Novartis Pharmaceuticals Corporation $17.4602/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384119 CMS
E.R. Squibb & Sons, L.L.C. $16.3702/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932530139 CMS
ABBVIE INC. $17.2101/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891617963 CMS
Amgen Inc. $8.2501/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939469777 CMS
Novartis Pharmaceuticals Corporation $17.7101/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894384115 CMS
E.R. Squibb & Sons, L.L.C. $14.8801/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932530127 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 17
PY2020 $314.72 33
PY2021 $919.34 66
PY2022 $634.09 41
PY2023 $61.34 4
PY2024 $241.07 21
PY2025 $115.35 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $172,640.25 7
PY2024 Recipient $104.58 1
PY2024 Principal investigator $382,387.43 9
PY2023 Principal investigator $336,411.57 23
PY2022 Recipient $119.00 1
PY2022 Principal investigator $317,946.58 63
PY2021 Principal investigator $333,885.98 38
PY2020 Recipient $169.00 1
PY2020 Principal investigator $109,610.11 16
PY2019 Principal investigator $188,780.60 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $831.67 12/31/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792489853
Principal investigator 1 GlaxoSmithKline, LLC. $8,074.80 12/27/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 860870961
Principal investigator 1 Eli Lilly and Company $1,007.09 12/16/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819467663
Principal investigator 1 ABBVIE INC. $2,156.26 12/02/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792485341
Principal investigator 1 GlaxoSmithKline, LLC. $13,844.70 12/01/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 860868603
Principal investigator 1 ABBVIE INC. $3,386.38 11/10/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792482579
Principal investigator 1 ABBVIE INC. $2,028.58 11/10/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) No dispute reported 06/30/2026 792482605
Principal investigator 1 Eli Lilly and Company $263.45 11/08/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819467481
Principal investigator 1 Eli Lilly and Company $578.07 10/26/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 819467665
Principal investigator 1 GlaxoSmithKline, LLC. $11,574.00 10/25/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809522967
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,000.00 10/20/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY OF SECUKINUMAB TO COMPARE 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO ARE RANDOMIZED TO DOSE ESCALATION AFTER NOT ACHIEVING INACTIVE DISEASE DURING AN INITIAL 16 WEEK OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG(ASLEAP) No dispute reported 06/30/2026 800642211
Principal investigator 1 ABBVIE INC. $9,486.94 10/07/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792478707
Principal investigator 1 ABBVIE INC. $2,782.72 10/06/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) No dispute reported 06/30/2026 792477757
Principal investigator 1 GlaxoSmithKline, LLC. $6,721.20 09/27/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809536745
Principal investigator 1 ABBVIE INC. $2,197.80 09/08/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792474621
Principal investigator 1 GlaxoSmithKline, LLC. $11,304.00 09/01/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809484425
Principal investigator 1 ABBVIE INC. $8,564.04 07/29/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792470699
Principal investigator 1 ABBVIE INC. $906.90 07/29/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) No dispute reported 06/30/2026 792470723
Principal investigator 1 GlaxoSmithKline, LLC. $9,556.20 07/23/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809493355
Principal investigator 1 GlaxoSmithKline, LLC. $5,978.70 07/12/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809482443
Principal investigator 1 ABBVIE INC. $7,390.90 06/30/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792465657
Principal investigator 1 GlaxoSmithKline, LLC. $5,715.00 06/09/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809488383
Principal investigator 1 ABBVIE INC. $2,843.68 05/27/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792460939
Principal investigator 1 ABBVIE INC. $6,800.00 05/27/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) No dispute reported 06/30/2026 792460949
Principal investigator 1 ABBVIE INC. $150.08 05/10/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792456209
Principal investigator 1 Eli Lilly and Company $22.95 05/10/2021 Non-covered Recipient Entity
CAHABA RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819452559
Principal investigator 1 Eli Lilly and Company $7.65 05/10/2021 Non-covered Recipient Entity
JOHN MUIR MED FNDTN DBA JOHN MUIR PHYS NETWORK
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819458463
Principal investigator 1 Eli Lilly and Company $29.25 05/10/2021 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819462885
Principal investigator 1 Eli Lilly and Company $76.50 05/10/2021 Non-covered Recipient Entity
SHARP MESA VISTA HOSPITAL
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819466827
Principal investigator 1 Eli Lilly and Company $18.75 05/10/2021 Non-covered Recipient Entity
RESEARCH AND CARDIOVASCULAR
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819468089
Principal investigator 1 Eli Lilly and Company $15.30 05/10/2021 Non-covered Recipient Entity
TEXAS DIABETES AND ENDOCRINOLOGY PA
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819469457
Principal investigator 1 GlaxoSmithKline, LLC. $9,090.00 05/03/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 809482941
Principal investigator 1 ABBVIE INC. $16,258.35 04/30/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792452665
Principal investigator 1 ABBVIE INC. $4,198.62 03/30/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792438709
Principal investigator 1 ABBVIE INC. $1,892.28 03/02/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792430523
Principal investigator 1 Novartis Pharmaceuticals Corporation $145,497.75 02/26/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A TWO-YEAR, PHASE III RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, EFFICACY, AND TOLERABILITY OF 300 MG S.C. SECUKINUMAB VERSUS PLACEBO, IN COMBINATION WITH SOC THERAPY, IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS No dispute reported 06/30/2026 800641261
Principal investigator 1 ABBVIE INC. $10,175.42 01/28/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC JOSEPH WIEGEL
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 792417051
Principal investigator 1 Eli Lilly and Company $18,460.00 01/05/2021 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 819467477